Figure 1 (Supplemental)



URO = urothelial layer INST = interstitial layer SM = smooth muscle LUM = lumen

Supplemental Figure 1. SPM receptor expression patterns do not change in response to CP or CP + SPMs (part 1). All panels are immunohistochemistry performed on 5 um sections of formalin-fixed, paraffin-embedded mouse bladders as described in the Methods section. Mice were subjected to the treatment paradigm shown in Figure 1. Sections are from control mice (Saline and PBS only treated mice; first 3 rows), CP-treated mice (injected with CP and saline only; 4th and 5th row) and CP + RvE1 (injected with CP and RvE1; 6th and 7th row). The primary antibody target is indicated on the top of each column and listed in Table 1. All sections in a given column were stained with the indicated antibody except for the first panel labeled "isotype". That panel was stained with the isotype control (Rabbit IgG Isotype Control from Novus Biologicals (Centennial, CO)) discussed in the methods section and listed in Table 1. All parameters for the slides used in this figure (incubation times, HRP product development times, etc.) were identical and identical antibody dilutions were used between Control, CP and CP + RvE1 samples. All slides specifically used in this figure were stained on the same day. Micrographs were taken with identical settings (exposure times, light intensity etc.). The rectangles indicated in the low magnification (Low mag) micrographs are expanded in the panels immediately below (the High Mag rows) to allow greater detail to be seen. Staining was repeated at least 3 times with similar results. Scale bars = 50 μm for 1st, 2nd, 4th and 6th columns (low mag) and 20 μm for the 3rd, 5th and 7th columns (high mag).

Figure 2 (Supplemental)



URO = urothelial layer INST = interstitial layer SM = smooth muscle LUM = lumen

Supplemental Figure 2. SPM receptor expression patterns do not change in response to CP or CP + SPMs (part 2). All panels are immunohistochemistry performed on 5 um sections of formalin-fixed, paraffin-embedded mouse bladders as described in the Methods section. Mice were subjected to the treatment paradigm shown in Figure 1 and sections are from control mice (Saline and PBS only treated mice; first 3 rows), CP-treated mice (injected with CP and saline only; 4th and 5th row) and CP + RvE1 (injected with CP and RvE1; 6th and 7th row). The primary antibody target is indicated on the top of each column and listed in Table 1. All sections in a given column were stained with the indicated antibody except for the first panel labeled "isotype". That panel was stained with the isotype control (Rabbit IgG Isotype Control from Novus Biologicals (Centennial, CO)) discussed in the methods section and listed in Table 1. All parameters for the slides used in this figure (incubation times, HRP product development times, etc.) were identical and identical antibody dilutions were used between Control, CP and CP + RvE1 samples. All slides specifically used in this figure were stained on the same day. Micrographs were taken with identical settings (exposure times, light intensity etc.). The rectangles indicated in the low magnification (Low mag) micrographs are expanded in the panels immediately below (the High Mag rows) to allow greater detail to be seen. Staining was repeated at least 3 times with similar results. Scale bars = 50 μm for 1st, 2nd, 4th and 6th columns (low mag) and 20 μm for the 3rd, 5th and 7th columns (high mag).